Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vyant Bio, Inc. (VYNT)

0.85   -0.18 (-17.48%) 02-03 15:16
Open: 0.987 Pre. Close: 1.03
High: 0.99 Low: 0.8123
Volume: 510,842 Market Cap: 5(M)

Technical analysis

as of: 2023-02-03 2:51:22 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.44     One year: 1.84
Support: Support1: 0.68    Support2: 0.56
Resistance: Resistance1: 1.23    Resistance2: 1.58
Pivot: 0.89
Moving Average: MA(5): 0.94     MA(20): 0.93
MA(100): 1.66     MA(250): 3.36
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 60.3     %D(3): 53.4
RSI: RSI(14): 44.7
52-week: High: 9.85  Low: 0.66
Average Vol(K): 3-Month: 426 (K)  10-Days: 120 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VYNT ] has closed above bottom band by 34.9%. Bollinger Bands are 67.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.04 - 1.05 1.05 - 1.05
Low: 0.95 - 0.96 0.96 - 0.96
Close: 1.02 - 1.03 1.03 - 1.04

Company Description

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Headline News

Fri, 03 Feb 2023
Is it Time to Dump Vyant Bio Inc (VYNT) Stock After it Is Down 7.61% in a Week? - InvestorsObserver

Fri, 03 Feb 2023
Small Nebraska startup hopes to challenge Pfizer, Merck in ... - Endpoints News

Fri, 03 Feb 2023
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway - Marketscreener.com

Fri, 03 Feb 2023
VYNT: Withdrawing Valuation - Yahoo Finance

Fri, 03 Feb 2023
Vyant CEO to step down as board plans to reduce workforce ... - Seeking Alpha

Wed, 11 Jan 2023
Where Does Vyant Bio Inc (VYNT) Stock Fall in the Biotechnology Field After It Is Up 36.36% This Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 29 (M)
% Held by Insiders 2.354e+007 (%)
% Held by Institutions 25 (%)
Shares Short 97 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.505e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 442.3
Return on Equity (ttm) -21.2
Qtrly Rev. Growth 1.08e+006
Gross Profit (p.s.) -0.01
Sales Per Share 0.13
EBITDA (p.s.) -0.39
Qtrly Earnings Growth -1.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 6.32
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 48820
Dividend Yield 0%
Dividend Pay Date 2019-10-24
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.